CytomX Therapeutics, Inc. CTMX
Regular-session close
After hours · Nov 19, 4:11 PM ET
- YTD
- -51.88%
- 1 year
- -43.53%
5D -0.01 (-0.49%)
- Market cap
- 446.91M
- Revenue (ttm)
- 76.20M
- Profit margin
- -22.79%
- EPS (ttm)
- -0.51
- Shares out
- 216.18M
- Forward P/E
- -9.74
- YTD return
- -51.88%
- 1-year return
- -43.53%
- 50-day average
- 4.92
- Volume
- 5.17M
- Avg volume
- 4.20M
- Open
- 1.88
- Previous close
- 1.88
- Day's range
- 1.87 – 2.07
- 52-week range
- 1.87 – 8.21
- Beta
- 2.48
- Analysts
- Strong Buy
- Price target
- 13.67 (+566.7%)
Key statistics
- 200-day average
- 3.77
- Enterprise value
- 677.28M
- Price / sales
- 13.08
- Price / book
- 7.92
- Revenue growth
- -98.30%
- Free cash flow
- -43.21M
- Total cash
- 137.05M
- Total debt
- 4.24M
- Return on equity
- -35.25%
- Short % of float
- 10.48%
Fundamental scorecard
3 of 25 checks passed on CTMX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2025 | Jun 1, 2025 | — | 0.00 | — | — |
| May 12, 2025 | Mar 1, 2025 | 0.18 | 0.27 | +0.09 | +50.00% |
| Mar 6, 2025 | Dec 1, 2024 | — | 0.22 | +0.42 | +210.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 23, 2026 | Piper Sandler | main | Overweight | Overweight |
| Mar 19, 2026 | Barclays | main | Overweight | Overweight |
| Mar 18, 2026 | Jefferies | main | Buy | Buy |
| Mar 18, 2026 | Guggenheim | main | Buy | Buy |
| Mar 17, 2026 | Wedbush | main | Outperform | Outperform |
| Mar 16, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cytomx.com
News
CytomX Therapeutics (NASDAQ:CTMX) and CareDx (NASDAQ:CDNA) Critical Analysis
CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
CytomX Therapeutics: Competitors Impress, Now Its Cytomx's Time To Shine JP Morgan Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12
CytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call Transcript Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $12
CytomX Therapeutics Q3 Earnings Call Highlights
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics Q3 2026 Earnings Call Transcript
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
Your note
Sign in to keep a note on CTMX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BELVIN MARCIA | Officer | Sale | Mar 16, 2026 | 300,760 |
| CHU YU-WAYE | Officer | Sale | Mar 16, 2026 | 189,446 |
| LANDAU JEFFREY B | Officer | Sale | Aug 19, 2024 | 126,736 |
| LESTER RACHAEL | Officer | Stock Award(Grant) | Feb 1, 2026 | 20,000 |
| MCCARTHY SEAN A. | Chief Executive Officer | Sale | Mar 16, 2026 | 1,172,080 |
| OGDEN CHRISTOPHER | Chief Financial Officer | Sale | Mar 16, 2026 | 296,948 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.51% | 24,688,109 | 113.81M | Dec 30, 2025 |
| VR Adviser, LLC | 9.14% | 15,561,500 | 71.74M | Dec 30, 2025 |
| Perceptive Advisors Llc | 5.69% | 9,680,185 | 44.63M | Dec 30, 2025 |
| Kynam Capital Management, LP | 5.27% | 8,966,077 | 41.33M | Dec 30, 2025 |
| Vanguard Group Inc | 4.98% | 8,475,584 | 39.07M | Dec 30, 2025 |
| Commodore Capital Lp | 4.52% | 7,692,300 | 35.46M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.78% | 4,726,133 | 21.79M | Dec 30, 2025 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.77% | 4,720,340 | 21.76M | Mar 30, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 2.00% | 3,400,000 | 15.67M | Feb 27, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.93% | 3,283,170 | 15.14M | Jan 30, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.89% | 3,222,510 | 14.86M | Jan 30, 2026 |
| Fidelity Securities Fund-Fidelity Series Small Cap Opportunities Fund | 1.49% | 2,531,495 | 11.67M | Jan 30, 2026 |
